Aardvark Therapeutics/$AARD
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Aardvark Therapeutics
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Ticker
$AARD
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
26
ISIN
US0029421007
Website
AARD Metrics
BasicAdvanced
$302M
-
-$4.40
-
-
Price and volume
Market cap
$302M
52-week high
$16.32
52-week low
$4.88
Average daily volume
63K
Financial strength
Current ratio
25.862
Quick ratio
25.311
Long term debt to equity
0.223
Total debt to equity
0.482
Profitability
EBITDA (TTM)
-31.065
Management effectiveness
Return on equity (TTM)
-34.70%
Valuation
Price to book
2
Price to tangible book (TTM)
2
Price to free cash flow (TTM)
-3.204
Free cash flow yield (TTM)
-31.22%
Free cash flow per share (TTM)
-434.52%
Growth
Earnings per share change (TTM)
121.84%
Bulls say / Bears say
Aardvark Therapeutics' lead candidate, ARD-101, demonstrated significant efficacy in a Phase 2 trial for Prader-Willi Syndrome (PWS), showing up to a 16-point reduction in hyperphagia scores, with an average reduction of approximately 8 points among protocol-following subjects. (Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights)
The company successfully completed its initial public offering (IPO) in February 2025, raising $97.9 million in gross proceeds, bolstering its financial position to support ongoing and future pipeline development. (Aardvark Therapeutics Announces Pricing of Initial Public Offering)
Aardvark has a strong cash position of $151.3 million as of March 31, 2025, projected to fund operations into 2027, providing a solid financial runway for its clinical programs. (Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights)
Aardvark reported a net loss of $9.3 million for Q1 2025, an increase from $2.2 million in Q1 2024, indicating rising operational expenses. (Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights)
The company's lead candidate, ARD-101, is still in clinical development, with Phase 3 HERO trial data expected in early 2026, meaning potential revenue generation is not imminent. (Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights)
Aardvark operates in the highly competitive field of metabolic disease therapeutics, facing potential challenges from established players and emerging treatments. (Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights)
Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2025.
AARD News
AllArticlesVideos
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
GlobeNewsWire·1 week ago
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
GlobeNewsWire·2 months ago
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aardvark Therapeutics stock?
Aardvark Therapeutics (AARD) has a market cap of $302M as of July 04, 2025.
What is the P/E ratio for Aardvark Therapeutics stock?
The price to earnings (P/E) ratio for Aardvark Therapeutics (AARD) stock is 0 as of July 04, 2025.
Does Aardvark Therapeutics stock pay dividends?
No, Aardvark Therapeutics (AARD) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Aardvark Therapeutics dividend payment date?
Aardvark Therapeutics (AARD) stock does not pay dividends to its shareholders.
What is the beta indicator for Aardvark Therapeutics?
Aardvark Therapeutics (AARD) does not currently have a Beta indicator.